Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8KMEG)

Drug Name

6-Methyl-2-p-tolyl-chromen-4-one Drug Info

Synonyms

88952-74-3; CHEMBL133226; 6-methyl-2-(4-methylphenyl)chromen-4-one; 6-methyl-2-(4-methylphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 6-methyl-2-(4-methylphenyl)-; 6-Methyl-2-p-tolyl-chromen-4-one; ACMC-20lfbb; AC1LFDMB; 4',6-Dimethylflavone; BAS 01121723; Oprea1_016511; Oprea1_052018; SCHEMBL10024074; CTK3A4544; DTXSID70354567; MolPort-000-450-864; ZINC265995; STK888587; AKOS000603226; MCULE-9170697941; NCGC00320777-01; 6-methyl-2-(p-tolyl)-4H-chromen-4-one; ST45177106; AB00086662-03; AB00086662-01

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 776388
CAS Number: CAS 88952-74-3
TTD Drug ID: DM8KMEG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Gamma-aminobutyric acid receptor (GAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[2]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[3]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[4]
Clonazepam	DMTO13J	Absence epilepsy		Approved	[5]
Piperazine	DMTY9LU	Ascariasis	1F62	Approved	[6]
Alpidem	DMN7Y9K	Anxiety disorder	6B00-6B0Z	Approved	[7]
Moxidectin	DMYGHX5	Onchocerciasis	1F6A	Approved	[8]
DP-VPA	DMGOXPQ	Bipolar disorder	6A60	Approved	[9]
ANDROSTERONE	DMITJAK	N. A.	N. A.	Phase 3	[3]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gamma-aminobutyric acid receptor (GAR)	TTNJYV2	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
2	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
3	Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
4	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
5	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
6	Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
7	Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
8	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
9	DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
10	Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.